FC-Gamma Receptor-Targeted Immunization for Breast Cancer
Abstract
Most of the recent progress in tumor vaccines has resulted from the identification of new tumor antigens and their epitopes, from advances in the understanding of the biology of antigen presentation, and delineation of the cell types and functions responsible for the induction of protective immunity. Recent studies have shown that proteins can be presented for Class II MHC processing via Fc gamma receptors expressed by leukocytes, with sufficient leakiness" in the process for proteins to exit endosomes and be processed for Class I MHC presentation as well. To translationally exploit such knowledge, we are testing the novel hypothesis that fusion of the extracellular domain (ECD) of the breast cancer antigen HER-2/neu to antibodies reactive with human Fc gamma receptor Ill (Fc gamma RIII) will promote specific immunization that confers resistance to the growth of tumors expressing HER-2/neu. The long-term goals of this project are to develop such fusion proteins for clinical use We will further refine this immunization strategy by introducing KDEL targeting signals and ubiquitin proteosome targeting sequences into the fusion proteins to direct the internalized antigen into both Class I and II processing pathways.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 1999
- Accession Number
- ADA381314
Entities
People
- Louis M. Weiner
Organizations
- Fox Chase Cancer Center